Santen Receives Excellence Award at NIKKEI Integrated Report Award 2024
March 28, 2025 – Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter Santen) announced that its integrated report, “Santen Report 2024,” was recognized with the Excellence Award at the NIKKEI Integrated Report Award 2024 organized by Nikkei Inc.
Santen publishes its annual integrated report, the “Santen Report,” to provide shareholders, investors and other stakeholders with easy-to-understand information about the company's strengths and medium- to long-term value creation based on the Core Principle of “Tenki ni sanyo suru.” “Santen Report 2024 (Year ended March 31, 2024)” introduces the company’s medium-term strategies and initiatives for growth—and the management foundation that serves as the basis for implementing these strategies—from financial and non-financial perspectives while communicating the company’s value-creation initiatives for patients and society.
The following points were cited when awarding the Excellence Award (excerpts from judge comments):
- Governance-related information is thorough. Following the skills matrix, the report provides an excellent description of the rationale behind the selection of new directors, efforts to improve the board of directors’ effectiveness, details of discussions within various committees, and the executive compensation system.
- How does Santen create value and utilize management resources based on its Core Principle? This is explained in a simple and concise manner through Santen’s history, value creation process, materiality and KPI progress, among others.
- Descriptions of initiatives in new fields such as myopia and ptosis are concrete and interesting.
- Sections containing a large amount of information are linked to websites, and links to related pages in the integrated report are also included, which is a thoughtful touch.
Santen will continue to engage in constructive dialogue with stakeholders, including shareholders and investors, and further enhance its information disclosure. Santen will continue to strive to contribute to society and enhance its corporate value, with the aim of realizing “Happiness with Vision” for everyone.
About the Santen Report 2024
More information about the report can be found here:
https://www.santen.com/en/ir/document/annual
About the NIKKEI Integrated Report Awards
More information about the awards can be found here:
https://adnet.nikkei.co.jp/a/nira (Japanese)
About Santen
As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”
For more information, please visit Santen’s website https://www.santen.com/en.
Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com
Official SNS
